Copper-64 and Copper-67: A Theranostic Pair

Introduction

Copper-64 and copper-67 are the same element, which is exactly why they make such a clean theranostic pair. Swap one isotope for the other and the chelator, the targeting peptide, and the chemistry all stay the same — only the nucleus changes, from a positron emitter you can image to a beta emitter that treats. ^{1, 3}

In theranostics, the ideal is a diagnostic scan that truly predicts the therapy: image the patient, see where the agent concentrates, and know that the therapeutic version will go to the same places in the same proportions. Pairs built from two different elements — a gallium imaging label and a lutetium therapy label, for example — approximate this, but the two agents are not chemically identical, so their biodistributions can differ subtly. A same-element pair removes that gap. Copper-64 for PET and copper-67 for beta therapy are isotopes of one element, so the imaging and therapy agents are chemically indistinguishable. ^{1, 2, 3}

This guide explains the physics that makes the copper pair work: the decay properties of each isotope, why the shared chemistry matters, how the isotopes are produced, how dosimetry carries from the diagnostic scan to the therapy plan, and the radiation-safety framework a copper program must satisfy. DRPS supports facilities building these programs through its PET/CT and nuclear medicine physics and radioactive material license support services across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

The physics of a matched pair

A theranostic pair couples an imaging radionuclide with a therapy radionuclide used on the same molecular target. The closer the two agents are chemically, the more faithfully the diagnostic image predicts the therapeutic dose distribution. ¹

The copper pair is about as close as it gets, because the two radionuclides are isotopes of a single element:

Copper-64 is a positron emitter, so a copper-64-labeled tracer produces a PET image. ⁴
Copper-67 is a beta-minus emitter, so a copper-67-labeled version of the same tracer delivers therapeutic dose. ²

Because copper is copper regardless of isotope, both agents use the same bifunctional chelator — for example DOTA, NOTA, or a sarcophagine cage amine — and the same targeting molecule, and they form chemically identical compounds. ^{1, 5, 6} The diagnostic scan is therefore a direct forecast of the therapy biodistribution, which is the central promise of theranostics. For background on the broader isotope landscape, see our overview of common PET and RPT isotopes.

Copper-64: an unusually versatile decay

Copper-64 has a half-life of about 12.7 hours. ³ What makes it unusual is that it decays by three routes at once — positron emission, electron capture, and beta-minus emission. ⁴ The positron branch is what enables PET, and its relatively modest positron energy gives good spatial resolution. The beta-minus and short-range electron components mean copper-64 even carries a therapeutic potential of its own. ⁴ For a dedicated program, though, copper-64's main job is imaging and treatment planning.

The roughly half-day half-life fits a same-day imaging workflow: the agent can be shipped from a production site, injected, and imaged over a few hours while enough activity remains. ¹

Copper-67: a beta therapy you can image

Copper-67 has a half-life of about 2.58 days and decays by beta-minus emission — the therapeutic workhorse — accompanied by gamma emissions near 93 and 185 keV. ² Those gamma lines are the quiet advantage: they fall in a range a gamma camera can image, so a clinician can perform SPECT during therapy to confirm where the dose actually went and to support patient-specific dosimetry. ² A therapy agent that images itself removes a layer of guesswork that pure beta or alpha emitters cannot.

The multi-day half-life suits the slower kinetics of a therapy agent, which needs time to accumulate in the target and clear from normal tissue.

Key Technical Principles

Decay math and why the half-lives fit their jobs

Both isotopes follow the universal decay law. The decay constant and the surviving fraction are

λ = \frac{ln 2}{T _{1/2}}, \frac{N ( t )}{N _{0}} = (\frac{1}{2})^{t / T_{1/2}} = e^{- λ t}

For copper-64, with $T_{1/2} \approx 12.7$ h, the fraction remaining one day after calibration is

\frac{N ( 24 h )}{N _{0}} = (\frac{1}{2})^{24/12.7} \approx 0.27

so about 27 percent of the activity survives to the next day — comfortable for a same-day PET study but too short to carry a multi-day therapeutic campaign. For copper-67, with $T_{1/2} \approx 2.58$ d, roughly 45 percent remains after three days,

\frac{N ( 3 d )}{N _{0}} = (\frac{1}{2})^{3/2.58} \approx 0.45

which matches the slower biology of a therapy agent. The pairing is not an accident: the imaging isotope is fast, the therapy isotope is slow, and both share one chemistry.

Carrying dosimetry from the scan to the therapy plan

The absorbed dose to a target region follows the MIRD schema:

\overset{ˉ}{D} (r_{T}) = r_{S} \sum \tilde{A} (r_{S}) S (r_{T} \leftarrow r_{S})

where $\tilde{A} (r_{S})$ is the time-integrated activity (the total number of decays) in each source region and $S (r_{T} \leftarrow r_{S})$ is the dose per decay from source to target. Because copper-64 and copper-67 share identical chemistry, the biodistribution — the shape of the uptake and clearance curves — measured with copper-64 PET predicts the copper-67 therapy biodistribution. The two differ mainly in their physical decay constants and in the energy each decay deposits, which are folded into $\tilde{A}$ and $S$ respectively. Investigators have formalized this companion relationship into abbreviated equations that estimate the copper-67 therapeutic dose from the copper-64 diagnostic uptake. ¹⁴ For the general framework, see our articles on the MIRD schema for internal dosimetry and radiopharmaceutical dosimetry under ICRP 128.

How the isotopes are produced

Production is where the copper pair is hardest. Copper-64 is most commonly made on a medical cyclotron by proton irradiation of enriched nickel-64, through the reaction

^{64} Ni (p, n)^{64} Cu

which uses an expensive enriched target; alternative routes using zinc targets, such as the proton-induced $^{68} Zn (p, n α)^{64} Cu$ reaction, have been demonstrated as potentially more cost-effective, with reported molar activities on the order of 155 GBq per micromole for DOTA labeling. ¹⁰ Copper-67 is produced on accelerators from zinc targets, and newer accelerator-neutron approaches can co-produce copper-64 and copper-67 from zinc with the required chemical separation of copper from zinc. ¹¹ The defining production challenge for therapy is specific activity — the ratio of radioactive to stable copper — because stable copper competes for chelator binding sites and dilutes the dose delivered per targeting molecule. ^{10, 11}

Property	Copper-64	Copper-67
Half-life	≈ 12.7 hours ³	≈ 2.58 days ²
Principal decay	positron, electron capture, beta-minus ⁴	beta-minus with gamma emissions (≈93, 185 keV) ²
Clinical role	PET imaging and treatment planning ⁷	beta therapy with SPECT monitoring ²
Typical production	cyclotron, nickel-64 target ¹⁰	accelerator, zinc target ¹¹
Representative agent	copper-64 DOTATATE; copper-64 SARTATE ^{7, 8}	copper-67 SARTATE ^{12, 13}

Clinical Impact

An approved imaging foothold

The copper platform already has an approved clinical presence. Copper-64 DOTATATE, a somatostatin-receptor PET agent for neuroendocrine tumors, was evaluated in a prospective, reader-masked U.S. clinical trial that reported an optimal imaging activity of 148 MBq (4.0 mCi) with 100 percent sensitivity and 96.8 percent specificity, and it received FDA approval in 2020 as Detectnet. ⁷ That gives the copper chemistry a validated diagnostic anchor on which a matched therapy can be built. For comparison with the gallium-based somatostatin agents, see our article on Ga-68 DOTATATE PET for neuroendocrine tumors.

The matched pair in people

The clearest demonstration of the full pair is SARTATE, a somatostatin-targeting agent built on a sarcophagine cage-amine chelator (MeCOSar) that binds copper tightly. ⁶ First-in-human copper-64 SARTATE PET showed high tumor uptake and retention, enough to support prospective dosimetry for therapy planning. ⁸ Investigators then administered the copper-64/copper-67 pair to patients, using copper-64 PET for treatment planning and copper-67 for therapy with whole-organ dosimetry, demonstrating that one chemistry can carry both the scan and the treatment in the same patient. ¹³ Preclinically, copper-67 SARTATE therapy was highly efficacious against a somatostatin-positive tumor model. ¹²

Beyond neuroendocrine tumors

The same matched-pair logic is being extended to other targets. Prostate-specific membrane antigen (PSMA) agents built for copper labeling have been evaluated preclinically as matched copper-64/copper-67 pairs, using copper-64 PET and copper-67 therapy on identical targeting molecules. ⁹ This remains an investigational, emerging direction rather than approved therapy, but it illustrates the appeal of a platform where imaging and therapy are chemically the same molecule. For the established approaches it would complement, see our article on Lu-177 DOTATATE PRRT for neuroendocrine tumors.

Practical Optimization Tips

For a facility considering or operating a copper theranostic program:

1. Treat specific activity as a program parameter

Confirm the specific activity of each copper-67 batch; stable-copper contamination reduces the dose delivered per targeting molecule. ^{10, 11}
Coordinate production logistics with the short copper-64 half-life for imaging and the longer copper-67 half-life for therapy.

2. Use the diagnostic scan as a real planning tool

Acquire copper-64 PET with dosimetry in mind — appropriate time points and quantitative calibration — so the biodistribution genuinely informs the copper-67 plan. ^{8, 14}
Exploit the copper-67 gamma emissions for SPECT verification during therapy. ²

3. Calibrate and verify quantitatively

Establish dose-calibrator settings and imaging calibration for both isotopes; copper-64 and copper-67 are different nuclides with different emissions and require their own settings.

4. Plan contamination control for a beta therapy

Build copper-67 workflows around contamination surveys, waste handling, and body-fluid precautions appropriate to a therapeutic beta emitter.

Common pitfalls to avoid

Assuming the copper-64 scan and copper-67 therapy are interchangeable without calibration. The chemistry is identical, but the nuclides, emissions, and instrument settings are not.
Ignoring specific activity. Low specific activity can quietly undercut therapeutic efficacy. ¹⁰
Copying a gallium or lutetium SOP onto copper. Half-lives, emissions, and production logistics differ.
Treating copper-67 as a pure beta emitter. Its imageable gammas are an asset for dosimetry, but they also contribute to the external dose that staff and the public receive. ²

Regulatory Considerations

A copper theranostic program is medical use of byproduct material, governed by the federal or Agreement State rules for radioactive material. Copper-64 and copper-67 are reactor- or accelerator-produced byproduct material, and a facility must hold the appropriate radioactive material license authorization before receiving, using, or administering them.

Key frameworks to reference:

10 CFR Part 20 — Standards for Protection Against Radiation, setting occupational and public dose limits that shape shielding, waste, and release decisions.
10 CFR Part 35 — Medical Use of Byproduct Material, which governs authorized users, written directives, patient release, and the radiation safety officer's responsibilities for therapy radionuclides.
10 CFR 35.1000 — the pathway for emerging medical uses not explicitly addressed elsewhere in Part 35, under which newer theranostic agents are often authorized.
NRC NUREG-1556, Volume 9 — program-specific guidance for medical-use licenses, including facility design, surveys, and radiation safety procedures.
USP General Chapter 825 — standards for the compounding, handling, and dispensing of radiopharmaceuticals, relevant when agents are prepared or labeled onsite.

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must verify which authority issues its license and which dose, survey, and reporting requirements apply before relying on any workflow assumption. Copper-67 therapy in particular should be coordinated with written directives, patient release calculations, contamination controls, staff training, radioactive material license support, and radiation safety officer program guidance. For the broader dosimetry obligations, see our article on Lu-177 theranostics dosimetry.

Frequently Asked Questions (FAQs)

What is a theranostic pair?

A theranostic pair is two radionuclides used with the same targeting molecule, one emitting radiation suited to imaging and one emitting radiation suited to therapy. When the two radionuclides are isotopes of the same element, the imaging agent and the therapy agent are chemically identical, so the biodistribution seen on the diagnostic scan predicts where the therapy dose will go.

Why are copper-64 and copper-67 considered a true matched pair?

They are isotopes of the same element, so they use identical chelators and form chemically identical compounds. Copper-64 emits positrons for PET imaging, and copper-67 emits beta particles for therapy. Because only the nucleus differs, the same labeled molecule can be made as an imaging agent or a therapy agent without changing its chemistry or biological behavior.

What are the key physical properties of copper-64 and copper-67?

Copper-64 has a half-life of about 12.7 hours and decays by positron emission, electron capture, and beta-minus emission, which is why it is used for PET and also carries therapeutic potential. Copper-67 has a half-life of about 2.58 days and decays by beta-minus emission with gamma emissions near 93 and 185 keV that allow SPECT imaging during therapy.

How are copper-64 and copper-67 produced?

Copper-64 is most commonly produced on a cyclotron by proton irradiation of enriched nickel-64, with alternative routes using zinc targets under study. Copper-67 is produced on accelerators from zinc targets, and achieving high specific activity, meaning a high ratio of radioactive to stable copper, is a central production challenge for therapy.

What is copper-64 DOTATATE used for?

Copper-64 DOTATATE is a PET imaging agent that targets somatostatin receptors, used to localize and stage neuroendocrine tumors. It was evaluated in a prospective U.S. clinical trial and received FDA approval in 2020 as Detectnet, giving the copper platform an approved clinical imaging foothold.

Does copper-67 therapy change the radiation-safety picture?

Copper-67 is a therapeutic beta emitter with imageable gamma emissions, so a program must address administered activity, contamination control, waste management, patient-specific dosimetry, and release instructions. In the United States, copper-67 therapy is medical use of byproduct material and generally falls under emerging-use licensing, with shielding and release decisions based on measured dose rates and the specific agent.

Key Takeaways

Same element, two jobs. Copper-64 images and copper-67 treats, and because both are copper, they share one chelator and one chemistry. ^{1, 3}
The decay properties fit their roles. Copper-64's roughly 12.7-hour half-life suits same-day PET; copper-67's 2.58-day half-life suits multi-day therapy. ^{2, 3}
Copper-67 images itself. Its gamma emissions near 93 and 185 keV enable SPECT verification and patient-specific dosimetry during therapy. ²
Dosimetry carries across the pair. Identical chemistry lets the copper-64 PET biodistribution predict the copper-67 therapy dose through the MIRD framework. ¹⁴
Production and specific activity are the hard part. Copper-64 from nickel-64 cyclotron targets and copper-67 from zinc accelerator targets, with specific activity as the key therapy parameter. ^{10, 11}
It is already clinically real. Copper-64 DOTATATE is FDA-approved, and the copper-64/copper-67 SARTATE pair has been used in patients. ^{7, 13}

Conclusion

The appeal of the copper pair is a kind of physical honesty: when the imaging agent and the therapy agent are the same element, the scan is not an approximation of the therapy — it is the therapy, minus the dose. Copper-64 and copper-67 let a single chelator and targeting molecule do double duty, imaging with positrons and treating with beta particles, while copper-67's gamma emissions let the treatment confirm itself.

The physics is favorable, but a program still has real work to do: securing high-specific-activity copper-67, calibrating quantitatively for two different nuclides, carrying dosimetry faithfully from scan to plan, and building a radiation-safety framework around a therapeutic beta emitter. Facilities that treat the copper pair as a coordinated system — production, imaging, dosimetry, therapy, and safety together — will be best positioned as these agents move from trials toward the clinic.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine facilities translate theranostic physics and radiation-safety requirements into practical, documented workflows. For copper and other theranostic programs, this may include PET/CT and nuclear medicine physics support, quantitative imaging and dose-calibrator setup, dosimetry program design, waste and contamination workflow review, staff training support, radioactive material license support, and radiation safety officer program guidance aligned with NRC and state requirements.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A theranostic program is strongest when the imaging and the therapy are built as one system — and copper makes that unusually literal.

Related Resources

References

Krasnovskaya OO, Abramchuck D, Erofeev A, et al. Recent advances in 64Cu/67Cu-based radiopharmaceuticals. International Journal of Molecular Sciences. 2023;24(11):9154. doi:10.3390/ijms24119154. doi.org
Hao G, Mastren T, Silvers W, et al. Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT. Scientific Reports. 2021;11(1):3622. doi:10.1038/s41598-021-82812-1. doi.org
Keinänen O, Fung K, Brennan JM, et al. Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy. Proceedings of the National Academy of Sciences. 2020;117(45):28316-28327. doi:10.1073/pnas.2009960117. doi.org
Peng F. Recent advances in cancer imaging with 64CuCl2 PET/CT. Nuclear Medicine and Molecular Imaging. 2022;56(2):80-85. doi:10.1007/s13139-022-00738-6. doi.org
Earley DF, Guillou A, Klingler S, et al. Photoactivatable bis(thiosemicarbazone) derivatives for copper-64 radiotracer synthesis. Dalton Transactions. 2022;51(13):5041-5052. doi:10.1039/d2dt00209d. doi.org
Paterson BM, Roselt P, Denoyer D, et al. PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. Dalton Transactions. 2014;43(3):1386-1396. doi:10.1039/c3dt52647j. doi.org
Delpassand ES, Ranganathan D, Wagh N, et al. 64Cu-DOTATATE PET/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial. Journal of Nuclear Medicine. 2020;61(6):890-896. doi:10.2967/jnumed.119.236091. doi.org
Hicks RJ, Jackson P, Kong G, et al. 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. Journal of Nuclear Medicine. 2019;60(6):777-785. doi:10.2967/jnumed.118.217745. doi.org
Lewis MR, Wang J, Carpenter RN, et al. Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen. Nuclear Medicine and Biology. 2024;136-137:108938. doi:10.1016/j.nucmedbio.2024.108938. doi.org
Nelson BJB, Wilson J, Andersson JD, Wuest F. 64Cu production via the 68Zn(p,nα)64Cu nuclear reaction: an untapped, cost-effective and high energy production route. Nuclear Medicine and Biology. 2024;128-129:108875. doi:10.1016/j.nucmedbio.2024.108875. doi.org
Nagai Y, Kawabata M, Hashimoto S, et al. Production of 64Cu and 67Cu with accelerator neutrons by deuterons and their separation from zinc. Frontiers in Nuclear Medicine. 2025;5:1657125. doi:10.3389/fnume.2025.1657125. doi.org
Cullinane C, Jeffery CM, Roselt PD, et al. Peptide receptor radionuclide therapy with 67Cu-CuSarTATE is highly efficacious against a somatostatin-positive neuroendocrine tumor model. Journal of Nuclear Medicine. 2020;61(12):1800-1805. doi:10.2967/jnumed.120.243543. doi.org
Bailey DL, Willowson KP, Harris M, et al. 64Cu treatment planning and 67Cu therapy with radiolabeled [64Cu/67Cu]MeCOSar-octreotate in subjects with unresectable multifocal meningioma: initial results for human imaging, safety, biodistribution, and radiation dosimetry. Journal of Nuclear Medicine. 2023;64(5):704-710. doi:10.2967/jnumed.122.264586. doi.org
Laffon E, Marthan R. An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [64Cu/67Cu]Cu-SARTATE. EJNMMI Research. 2021;11(1):75. doi:10.1186/s13550-021-00814-6. doi.org